Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma

Cancer

Volumn 115, Issue 22, 2009, Pages 5243-5250

  Abdeen, Ayesha ^a   Chou, Alexander J ^a   Healey, John H ^a   Khanna, Chand ^b   Osborne, Tanasa S ^b   Hewitt, Stephen M ^b   Kim, Mimi ^c   Wang, Dan ^c   Moody, Karen ^c   Gorlick, Richard ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Immunohistochemistry; Osteosarcoma; Signal transduction; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN; VASCULOTROPIN; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 3;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROTEIN ARRAY ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449372121     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24562     Document Type: Article

References (11)

1. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-1161. (Pubitemid 43297356)
2. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-638.
3. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449-453. (Pubitemid 23071040)
4. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;415:106-120. (Pubitemid 11217753)
5. Khanna C, Prehn J, Hayden D, et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res. 2002;8:2406-2412. (Pubitemid 34753616)
6. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18. (Pubitemid 8190735)
7. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
8. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
9. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6:572-577. (Pubitemid 30111481)
10. Hoang BH, Dyke JP, Koutcher JA, et al. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res. 2004;426:32-38.
11. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999;35:1089-1093.